Surgery and radiation for tumor removal is particularly challenging. The FDA-approved chemotherapy Temozolomide (TMZ) is effective in only fifty percent of cases, with rapid development of resistance among the cancer cells.
At Brain Chemistry Labs, we have taken an innovative approach to glioblastoma treatment based on cyclotides, small circular peptides, extracted from violets.
This led to the discovery[1][2] in vitro of several cyclotides that can turbocharge the power of TMZ to kill glioblastoma cells by as much as eightfold.
As these cyclotides are found only in minuscule concentrations in violets, we have commissioned equally effective synthetic versions that can be produced in quantities sufficient for clinical studies.
Currently we are exploring novel ways of integrating advanced techniques in pharmacology, medicinal chemistry, and ethnobotany to specifically target glioblastoma cells within the brain while at the same time leaving healthy brain tissue intact.
Our hope is that violet cyclotides will provide another powerful tool that can prevent development of resistance of glioblastoma cells to current TMZ therapy for both children and adults.
Future work will test the effectiveness of cyclotides, after they are shown to be safe, in human clinical trials.
Join us in supporting this highly impactful work.
- 1.
Gerlach SL, Metcalf JS, Dunlop RA, Banack SA, Her C, Krishnan VV, et al. Kalata B1 Enhances Temozolomide Toxicity to Glioblastoma Cells. Biomedicines. 2024;12:2216. doi:10.3390/biomedicines12102216
- 2.
Gerlach SL, Dunlop RA, Metcalf JS, Banack SA, Cox PA. Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide. J Nat Prod. 2022;85:34–46. doi:10.1021/acs.jnatprod.1c00595
In vitro
Violet cyclotides shown in the laboratory to strengthen the standard chemotherapy. Synthetic versions commissioned for clinical studies.
- SourceViolet cyclotides
- Partner drugTemozolomide (TMZ)
- EffectUp to eightfold
- NextSafety, then human trials

